Cystaran cysteamine hydrochloride ophthalmic solution regulatory update

FDA approved Cystaran cysteamine ophthalmic solution from Sigma-Tau to treat corneal cystine crystal accumulation in patients with cystinosis, a rare genetic lysosomal storage disease. The company said the price for the product, which is expected to launch in the U.S. next year, has not been set. Cystaran is an ophthalmic formulation of cysteamine, a degradation product of the amino acid cysteine. ...